Assessing kidney function and blood breakdown after a heart procedure for atrial fibrillation
The Assessment of Hemolysis and Renal Functions During and After Catheter Ablation for Atrial Fibrillation Using Pulsed-field Energy
This study is testing how a specific heart procedure affects kidney function and blood breakdown in people with atrial fibrillation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Charles University, Czech Republic Academic / other |
| Locations | 1 site (Prague) |
| Trial ID | NCT06198933 on ClinicalTrials.gov |
What this trial studies
This project aims to evaluate the effects of pulsed-field ablation on hemolysis and renal function in patients with atrial fibrillation. It will involve measuring red blood cell microparticles and hemoglobinuria immediately after the procedure and one to three days post-procedure. The study will include patients with paroxysmal and persistent atrial fibrillation who are eligible for catheter ablation, while excluding those with hematologic disorders or on dialysis. A total of 100 patients will be enrolled to assess the relationship between the number of ablation applications and the degree of hemolysis on renal function.
Who should consider this trial
Good fit: Ideal candidates are patients with symptomatic paroxysmal or non-paroxysmal atrial fibrillation indicated for catheter ablation.
Not a fit: Patients with known hematologic disorders, significant hepatic disease, or those on permanent hemodialysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve understanding of the safety and effects of pulsed-field ablation on kidney health in atrial fibrillation patients.
How similar studies have performed: While this approach is relatively novel, similar studies have explored the effects of catheter ablation on renal function, indicating potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * symptomatic paroxysmal or non-paroxysmal atrial fibrillation Exclusion Criteria: * known hematologic disorders * disorders associated with increased hemolysis * known significant hepatic disease * patient in permanent hemodialysis
Where this trial is running
Prague
- Cardiocenter, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady — Prague, Czech Republic (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.